Research progress on fecal microbiota transplantation in the treatment of obesity and metabolic dysfunction-associated steatotic liver disease

doi:10.3877/cma.j.issn.2095-9605.2024.02.011

Abstract

Abstract:

Gut microbiota dysbiosis plays a significant role in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Fecal microbiota transplantation (FMT), as a novel approach for gut microbiota modulation and therapy, has garnered considerable attention in the treatment of obesity and MASLD. Numerous clinical studies have been conducted in recent years both domestically and internationally, actively exploring its applications. FMT has shown limited direct efficacy in weight reduction for treating obesity and its effects on alleviating associated metabolic disorders remain unclear. However, it holds promise in weight management following bariatric surgery and may offer positive outcomes in improving hepatic steatosis among lean obese individuals and with MASLD subtypes. This paper summarizes and discusses the clinical evidence of FMT in the treatment of obesity and MASLD.

Key words: Obesity, Metabolic dysfunction-associated steatotic liver disease, Fecal microbiota transplantation, Therapeutic effects

Ting Feng, Junzhao Ye. Research progress on fecal microbiota transplantation in the treatment of obesity and metabolic dysfunction-associated steatotic liver disease[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2024, 10(02): 138-144.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2024.02.011

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2024/V10/I02/138

Figures/Tables 3

References 36

[1]	Zhou X, Zhang X, Yu J. Gut mycobiome in metabolic diseases: mechanisms and clinical implication [J]. Biomed J, 2023: 100625.
[2]	Jayachandran M, Qu S. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies [J]. Rev Endocr Metab Disord. 2023, 24(6): 1189-1204.
[3]	Quesada-Vázquez S, Castells-Nobau A, Latorre J, et\ al. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity [J]. Cell Rep Med, 2023, 4(12): 101341.
[4]	Schmidt TSB, Li SS, Maistrenko OM, et al. Drivers and determinants of strain dynamics following fecal microbiota transplantation [J]. Nat Med, 2022, 28(9): 1902-1912.
[5]	van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile [J]. N Engl J Med, 2013, 368(5): 407-415.
[6]	Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recur rent Clostridium difficile infection: a randomized trial [J]. Ann Intern Med, 2016, 165(9): 609-616.
[7]	Nicholson MR, Mitchell PD, Alexander E, et al. Efficacy of fecal microbiota transplantation for Clostridium difficile infec tion in children [J]. Clin Gastroenterol Hepatol, 2020, 18(3): 612-619.
[8]	Peery AF, Kelly CR, Kao D, et al; AGA Clinical Guidelines Committee. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases [J]. Gastroenterology, 2024, 166(3): 409-434.
[9]	Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection [J]. Aliment Pharmacol Ther, 2017, 46(5): 479-493.
[10]	Leong KSW, Jayasinghe TN, Wilson BC, et al. Effects of fecal microbiome transfer in adolescents with obesity: the Gut Bugs Randomized Controlled Trial [J]. JAMA Netw Open, 2020, 3(12): e2030415.
[11]	Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial [J]. Am J Gastroenterol. 2020, 115(7): 1055-1065.
[12]	Witjes JJ, Smits LP, Pekmez CT, et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis [J]. Hepatol Commun, 2020, 4(11): 1578-1590.
[13]	Zhou X, Chen R, Cai Y, et al. Fecal microbiota transplantation: a prospective treatment for type 2 diabetes mellitus [J]. Diabetes Metab Syndr Obes, 2024, 17: 647-659.
[14]	Zhong HJ, Zeng HL, Cai YL, et al. Washed microbiota transplantation lowers blood pressure in patients with hypertension [J]. Front Cell Infect Microbiol, 2021, 11: 679624.
[15]	Liang F, Lu X, Deng Z, et al. Effect of washed microbiota transplantation on patients with dyslipidemia in South China [J]. Front Endocrinol (Lausanne), 2022, 13: 827107
[16]	Xie WR, Yang XY, Deng ZH, et al. Effects of Washed Microbiota Transplantation on Serum Uric Acid Levels, Symptoms, and Intestinal Barrier Function in Patients with Acute and Recurrent Gout: A Pilot Study [J]. Dig Dis, 2022, 40(5): 684-690.
[17]	Yu Y, Wang W, Zhang F. The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome [J]. Adv Sci (Weinh), 2023, 10(35): e2301097.
[18]	Shi Q, editors. Nanjing consensus on methodology of washed microbiota transplantation [J]. Chin Med J (Engl), 2020, 133(19): 2330-2332.
[19]	Zhang T, Lu G, Zhao Z, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening [J]. Protein Cell, 2020, 11(4): 251-266.
[20]	Zhang T, Lu G, Zhao Z, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening [J]. Protein Cell, 2020, 11(4): 251-266.
[21]	Youngster I, Eshel A, Geva M, et al. Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study [J]. Bone Marrow Transplant, 2024, 59(3): 409-416.
[22]	Stefansson M, Bladh O, Flink O, et al. Safety and tolerability of frozen, capsulized autologous faecal microbiota transplantation. A randomized double blinded phase I clinical trial [J]. PLoS One, 2023, 18(9): e0292132.
[23]	Hu D, Zhao J, Zhang H, et al[. Fecal Microbiota Transplantation for Weight and Glycemic Control of Obesity as Well as the Associated Metabolic Diseases: Meta-Analysis and Comprehensive Assessment [J]. Life (Basel), 2023, 13(7): 1488.
[24]	Zecheng L, Donghai L, Runchuan G, et al. Fecal microbiota transplantation in obesity metabolism: A meta-analysis and systematic review [J]. Diabetes Res Clin Pract, 2023, 202: 110803.
[25]	Ghorbani Y, Schwenger KJP, Sharma D, et al. Effect of faecal microbial transplant via colonoscopy in patients with severe obesity and insulin resistance: A randomized double-blind, placebo-controlled Phase 2 trial [J]. Diabetes Obes Metab, 2023, 25(2): 479-490.
[26]	Lahtinen P, Juuti A, Luostarinen M, et al. Effectiveness of fecal microbiota transplantation for weight loss in patients with obesity undergoing bariatric surgery: a randomized clinical trial [J]. JAMA Netw Open, 2022, 5(12): e2247226.
[27]	Rinott E, Youngster I, Yaskolka Meir A, et al. Effects of diet-modulated autologous fecal microbiota transplantation on weight regain [J]. Gastroenterology, 2021, 160(1): 158-173. e10.
[28]	Kamer O, Rinott E, Tsaban G, et al. Successful weight regain attenuation by autologous fecal microbiota transplantation is associated with non-core gut microbiota changes during weight loss; randomized controlled trial [J]. Gut Microbes, 2023, 15(2): 2264457.
[29]	Xue L, Deng Z, Luo W, et al. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial [J]. Front Cell Infect Microbiol, 2022, 12: 759306.
[30]	Stols-Gonçalves D, Mak AL, Madsen MS, et al. Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: a multi-omics approach [J]. Gut Microbes, 202, 15(1): 2223330.
[31]	Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial [J]. Am J Gastroenterol, 2020, 115(7): 1055-1065.
[32]	Qiu XX, Cheng SL, Liu YH, et al. Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect [J]. World J Gastroenterol, 2024, 30(8): 833-842.
[33]	Pakmehr A, Mousavi SM, Ejtahed HS, et al. The Effect of fecal microbiota transplantation on cardiometabolic risk factors: a systematic review and meta-analysis[J]. Clin Ther, 2024, 46(2): e87-e100.
[34]	Yu EW, Gao L, Stastka P, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial [J]. PLoS Med, 2020, 17(3): e1003051.
[35]	Ding D, Yong H, You N, et al. Prospective study reveals host microbial determinants of clinical response to fecal microbiota transplant therapy in type 2 diabetes patients [J]. Front Cell Infect Microbiol, 2022, 12: 820367.
[36]	Kamal FD, Dagar M, Reza T, et al. Beyond diet and exercise: the impact of gut microbiota on control of obesity [J]. Cureus, 2023, 15(11): e49339.

作者，年份	国家	研究对象	研究分组	研究时间	观察指标	临床有效性	代谢物改变	肠道菌群改变
Hu D et al. ^[23] 2023	中国	肥胖	Meta		HOMA-IR、HbA1c水平、体重、BMI	HOMA-IR等指标均明显降低
Zecheng L et al. ^[24] 2023	中国	肥胖	Meta		HOMA-IR、血压、血脂、空腹血糖、CRP、乙酸、膳食热量摄入	HOMA-IR等指标均明显降低
Ghorbani Y et al. ^[25] 2023	加拿大	肥胖	RCT，异体FMT vs.自体FMT	FMT治疗后1月	HOMA-IR、HbA1c水平、血脂谱、体重、肠道激素、内毒素、食欲测量、肠道菌群、血清/粪便代谢物、生活质量、焦虑和抑郁评分	HOMA-IR等临床指标均无统计学意义	增加：粪便中的吲哚乙酸和丁烯基肉减少：血清喹啶酮	增加：腐球菌属、双歧杆菌属、拟杆菌属和玫瑰布里菌属减少：链球菌属
				FMT治疗后3月				增加：拟杆菌属和布劳提菌属
Lahtinen P et al. ^[26] 2022	芬兰	肥胖	RCT，异体FMT vs自体FMT	FMT治疗后6、18月	体重下降比例	体重下降比例无统计学意义
Rinott E et al. ^[27] 2021 & Kamer O et al. ^[28] 2023	以色列	肥胖	RCT，饮食调节自体FMT胶囊vs.安慰剂	FMT治疗后8月	体重回升、胃肠道症状、腰围、血糖状态、肠道菌群变化	体重回升、腰围增加、胰岛素水平反弹均减缓		增加：马赛拟杆菌和帕拉普氏菌属

作者，年份	国家	研究对象	研究分组	研究时间	观察指标	临床有效性	代谢物改变	肠道菌群改变
Hu D et al. ^[23] 2023	中国	肥胖	Meta		HOMA-IR、HbA1c水平、体重、BMI	HOMA-IR等指标均明显降低
Zecheng L et al. ^[24] 2023	中国	肥胖	Meta		HOMA-IR、血压、血脂、空腹血糖、CRP、乙酸、膳食热量摄入	HOMA-IR等指标均明显降低
Ghorbani Y et al. ^[25] 2023	加拿大	肥胖	RCT，异体FMT vs.自体FMT	FMT治疗后1月	HOMA-IR、HbA1c水平、血脂谱、体重、肠道激素、内毒素、食欲测量、肠道菌群、血清/粪便代谢物、生活质量、焦虑和抑郁评分	HOMA-IR等临床指标均无统计学意义	增加：粪便中的吲哚乙酸和丁烯基肉减少：血清喹啶酮	增加：腐球菌属、双歧杆菌属、拟杆菌属和玫瑰布里菌属减少：链球菌属
				FMT治疗后3月				增加：拟杆菌属和布劳提菌属
Lahtinen P et al. ^[26] 2022	芬兰	肥胖	RCT，异体FMT vs自体FMT	FMT治疗后6、18月	体重下降比例	体重下降比例无统计学意义
Rinott E et al. ^[27] 2021 & Kamer O et al. ^[28] 2023	以色列	肥胖	RCT，饮食调节自体FMT胶囊vs.安慰剂	FMT治疗后8月	体重回升、胃肠道症状、腰围、血糖状态、肠道菌群变化	体重回升、腰围增加、胰岛素水平反弹均减缓		增加：马赛拟杆菌和帕拉普氏菌属

作者,年份	国家	研究对象	研究分组	研究时间	观察指标	临床有效性	肠道菌群改变
Xue L et al. ^[29] 2022	中国	MASLD	RCT，异体FMT vs.口服益生菌	治疗1月后	脂肪衰减系数	瘦人MASLD的平均脂肪衰减系数降至正常水平，肥胖MASLD的脂肪衰减系数未见明显变化	瘦人MASLD：增加：塞氏单甲酸杆菌目、威隆氏菌科、普雷沃特拉氏菌属、真杆菌属、罗斯贝里亚菌属、瘤胃链球菌组减少：放线菌门、硫还原弧菌目、拟杆菌属肥胖MASLD：增加：瘤胃链球菌组、普雷沃特拉氏菌属、乳酸杆菌丰度减少：Rikenella RC9肠道菌群、另枝菌属
Stols-Gonçalves D et al. ^[30] 2021	荷兰	MASLD	RCT，素食为主的异体FMT vs.自体FMT	第24周	肝活检相关评分，谷氨酰转肽酶	炎症坏死评分出现了临界差异，总的脂肪肝活动度评分及纤维化程度均未见差异，异源性FMT组的谷氨酰转肽酶水平下降
Craven L et al.^[31] 2020	加拿大和英国	MASLD	RCT，异体FMT vs.自体FMT	FMT治疗后6个月	HOMA-IR，肝脏PDFF，肠道通透性	FMT未能改善以HOMA-IR或肝脏PDFF测量的IR，有潜力减少小肠通透性
Qiu XX et al. ^[32] 2024	中国	MASLD	Meta		血脂、转氨酶、HOMA-IR、BMI	HOMA-IR等临床指标均无统计学意义
Yu EW et al. ^[34] 2020	伊朗	MASLD	Meta		糖化血红蛋白、胰岛素水平、血脂、血糖、人体测量指标、肠道菌群	FMT可减少糖化血红蛋白、胰岛素水平，增加HDL水平	增加：梭杆菌属、坎氏肠球菌、无氧链球菌属、厚壁梭菌和原肠球菌属，拟杆菌和普雷沃氏菌属以及双歧杆菌属减少：梭杆菌属和瘤胃球菌属

作者,年份	国家	研究对象	研究分组	研究时间	观察指标	临床有效性	肠道菌群改变
Xue L et al. ^[29] 2022	中国	MASLD	RCT，异体FMT vs.口服益生菌	治疗1月后	脂肪衰减系数	瘦人MASLD的平均脂肪衰减系数降至正常水平，肥胖MASLD的脂肪衰减系数未见明显变化	瘦人MASLD：增加：塞氏单甲酸杆菌目、威隆氏菌科、普雷沃特拉氏菌属、真杆菌属、罗斯贝里亚菌属、瘤胃链球菌组减少：放线菌门、硫还原弧菌目、拟杆菌属肥胖MASLD：增加：瘤胃链球菌组、普雷沃特拉氏菌属、乳酸杆菌丰度减少：Rikenella RC9肠道菌群、另枝菌属
Stols-Gonçalves D et al. ^[30] 2021	荷兰	MASLD	RCT，素食为主的异体FMT vs.自体FMT	第24周	肝活检相关评分，谷氨酰转肽酶	炎症坏死评分出现了临界差异，总的脂肪肝活动度评分及纤维化程度均未见差异，异源性FMT组的谷氨酰转肽酶水平下降
Craven L et al.^[31] 2020	加拿大和英国	MASLD	RCT，异体FMT vs.自体FMT	FMT治疗后6个月	HOMA-IR，肝脏PDFF，肠道通透性	FMT未能改善以HOMA-IR或肝脏PDFF测量的IR，有潜力减少小肠通透性
Qiu XX et al. ^[32] 2024	中国	MASLD	Meta		血脂、转氨酶、HOMA-IR、BMI	HOMA-IR等临床指标均无统计学意义
Yu EW et al. ^[34] 2020	伊朗	MASLD	Meta		糖化血红蛋白、胰岛素水平、血脂、血糖、人体测量指标、肠道菌群	FMT可减少糖化血红蛋白、胰岛素水平，增加HDL水平	增加：梭杆菌属、坎氏肠球菌、无氧链球菌属、厚壁梭菌和原肠球菌属，拟杆菌和普雷沃氏菌属以及双歧杆菌属减少：梭杆菌属和瘤胃球菌属

Please choose a citation manager

Content to export